SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at least 30 per cent. Heather H Cheng MD PhD, who is a Senior Reseach Fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington, presented her results at a poster session of the 2014 ASCO Genitourinary Cancers Symposium.
CONTACT:
Heather H Cheng MD PhD
Senior Reseach Fellow
Fred Hutchinson Cancer Research Center
Seattle, Washington 98109
SOURCE:
2014 ASCO Genitourinary Symposium, San Francisco
Abstract 18
“The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC”
ABSTRACT LINK:
http://meetinglibrary.asco.org/content/124184-142
